Saol Therapeutics Acquires Three Hyperimmune Products from Aptevo Therapeutics

DFW Capital Partners is pleased to announce that its existing portfolio company, Saol Therapeutics, has acquired to acquire three marketed hyperimmune products, WinRho® SDF (Rh0(D) Immune Globulin Intravenous (Human)), HepGam B® (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG® (Varicella Zoster Immune Globulin (Human)) from Aptevo Therapeutics Inc. (Nasdaq: APVO). The deal includes both upfront… Read more »

Evolution Research Group acquires Endeavor Clinical Trials

DFW Capital Partners is pleased to announce that its existing portfolio company, Evolution Research Group (“ERG”), has acquired Endeavor Clinical Trials (“ECT”), of San Antonio, Texas. ECT has over 20 years of experience conducting over 185 clinical trials, specializing in post-operative pain, neuropathic pain, podiatry, and vaccine research, among others. Endeavor Clinical Trials is comprised… Read more »

DFW Capital Partners Combines LRI and RTS into Integrated Efficiency Solutions

DFW Capital Partners (“DFW”) today announced that Integrated Efficiency Solutions (“IES”), a new holding company, has continued its commitment to the energy solutions market with its third investment. On June 30, 2017, IES acquired Retro-Tech Systems (“RTS”) as a wholly owned subsidiary. RTS, which includes RTS Lighting, RTS Water, RTS Utility Metering, and RTS Building… Read more »

Superior Controls Merges with Banks Integration Group

DFW Capital Partners is pleased to announce that its existing portfolio company, Superior Controls, a leading control system integrator of custom industrial automation and IT solutions, has merged with Banks Integration Group (“Banks Integration”), a leading systems integrator headquartered in Vacaville, CA outside San Francisco.  The combination, which is the first investment of its kind for… Read more »